 Drug Resistance, Viral
"Drug Resistance, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of viruses to resist or to become tolerant to chemotherapeutic agents or antiviral agents. This resistance is acquired through gene mutation.
| Descriptor ID |
D024882
|
| MeSH Number(s) |
G06.225.420 G06.920.225 G07.690.773.984.269.420
|
| Concept/Terms |
Drug Resistance, Viral- Drug Resistance, Viral
- Drug Resistances, Viral
- Antiviral Drug Resistance
- Antiviral Drug Resistances
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Viral".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Viral".
This graph shows the total number of publications written about "Drug Resistance, Viral" by people in this website by year, and whether "Drug Resistance, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 | | 2002 | 2 | 1 | 3 | | 2003 | 4 | 2 | 6 | | 2004 | 2 | 4 | 6 | | 2005 | 3 | 2 | 5 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 2 | 4 | | 2008 | 3 | 2 | 5 | | 2009 | 2 | 1 | 3 | | 2010 | 1 | 3 | 4 | | 2011 | 0 | 4 | 4 | | 2012 | 2 | 3 | 5 | | 2013 | 2 | 0 | 2 | | 2014 | 4 | 5 | 9 | | 2015 | 1 | 4 | 5 | | 2016 | 3 | 2 | 5 | | 2017 | 3 | 3 | 6 | | 2018 | 2 | 1 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 0 | 2 | 2 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 2 | 0 | 2 | | 2025 | 6 | 2 | 8 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance, Viral" by people in Profiles.
-
Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM. HIV Resistance to Dolutegravir Varies With Coadministered Agents. Clin Infect Dis. 2026 Apr 30; 82(4):592-596.
-
Pasco R, Hayden FG, Meyers LA. Modeling Influenza Antiviral Strategies: Reducing Burden and Preventing Resistance. J Infect Dis. 2025 Oct 17; 232(Supplement_3):S299-S308.
-
Rogg L, Underwood M, Hanan N, Castillo-Mancilla JR, Kahl L, Halliday F, Ghita GL, Jeffrey JL, Byrne S, Onodera T, Horton J, Gartland M. Phase 1 Evaluation of VH4524184, a Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2025 Oct 06; 81(3):510-520.
-
Scallon AJ, Maheria P, Oyaro P, Thomas KK, Chohan BH, Odhiambo F, Brown E, Ochomo E, Karauki E, Yongo N, Hassan SA, Bishop MD, Beck IA, Boyce C, Frenkel LM, Abuogi L, Patel RC. Clinical, Psychosocial, and Structural Factors Associated with the Detection of HIV Drug Resistance in Children Living with HIV in Kisumu, Kenya: Secondary Analysis of Data from the Opt4Kids Study. Viruses. 2025 Sep 16; 17(9).
-
Parikh UM, Kudrick LD, Levy L, Bosek E, Chohan BH, Mukui I, Masyuko S, Ndlovu N, Mahaka I, Mugurungi O, Ncube G, Hettema A, Matse SN, Mullick S, Wallis CL, Heaps AL, Penrose KJ, McCormick KD, Wiesner L, Anderson PL, Peterson JM, Celum C, Richardson BA, Castor D, Allen S, Torjesen K, Mellors JW. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025 Aug; 28(8):e70011.
-
Han WM, Solomon SS, Smeaton L, Avihingsanon A, Wagner Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D. Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial. Clin Infect Dis. 2025 Jul 18; 80(6):1293-1301.
-
Muthu Ramalingam B, Sears JD, Talbot KM, Su YN, Houliston S, Hossain MA, Davis-Gilbert ZW, Zhao C, Oh HJ, Brown PJ, Sanders MK, Moorman SR, Ojha D, Burdick JE, Law I, Morales NL, Martinez SA, Loppnau P, Garcia Perez J, Drobish AM, Morrison TE, Streblow ZJ, Streblow DN, Arrowsmith CH, Vargason A, Couñago RM, Halabelian L, Arnold JJ, Cameron CE, Moorman NJ, Heise MT, Willson TM. Identification of Direct-Acting nsP2 Helicase Inhibitors with Antialphaviral Activity. J Med Chem. 2025 Jul 24; 68(14):14514-14536.
-
Briganti L, Annamalai AS, Bester SM, Wei G, Andino-Moncada JR, Singh SP, Kleinpeter AB, Tripathi M, Nguyen B, Radhakrishnan R, Singh PK, Greenwood J, Schope LI, Haney R, Huang S-W, Freed EO, Engelman AN, Francis AC, Kvaratskhelia M. Structural and mechanistic bases for resistance of the M66I capsid variant to lenacapavir. mBio. 2025 May 14; 16(5):e0361324.
-
Yin P, Sobolik EB, May NA, Wang S, Fayed A, Vyshenska D, Drobish AM, Parks MG, Lello LS, Merits A, Morrison TE, Greninger AL, Kielian M. Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4'-Fluorouridine. PLoS Pathog. 2025 Jan; 21(1):e1012859.
-
Dinh T, Tber Z, Rey JS, Mengshetti S, Annamalai AS, Haney R, Briganti L, Amblard F, Fuchs JR, Cherepanov P, Kim K, Schinazi RF, Perilla JR, Kim B, Kvaratskhelia M. The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir. mBio. 2024 Nov 13; 15(11):e0046524.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|